Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

University of Toronto

$62,500.00

Beyond Cardiotoxicity: Characterizing the Short and Long-term Cardiovascular Side Effects of Breast Cancer Endocrine Treatment

FY 2022-23

Summary
In the last 15 years, ~300,000 Canadian women have survived breast cancer (BC) thanksto improvementsin BC treatment. However, BC treatments can also be harmful for the heart and vessels, leaving BC survivors at an increased risk of dying from heart, stroke and Alzheimer’s diseases. One BC treatment called aromatase inhibitors appear to increase the risk of cardiovascular mortality by 50%. Despite this, very few studies have looked at the direct effects of aromatase inhibitors on the heart, vessels, and other early risk factorsfor cardiovascular disease. Thisstudy will be the first to examine the short- and long-term impact of aromatase inhibitors on a suite of health indicesrelated to heart, vessel, and brain health in BC survivors.
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
488204
Name
Kirkham Amy A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Beyond Cardiotoxicity: Characterizing the Short and Long-term Cardiovascular Side Effects of Breast Cancer Endocrine Treatment
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$62,500
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Decreasing Secondary Effects Of Treatment; Targets And Biomarkers
Abstract
In the last 15 years, ~300,000 Canadian women have survived breast cancer (BC) thanksto improvementsin BC treatment. However, BC treatments can also be harmful for the heart and vessels, leaving BC survivors at an increased risk of dying from heart, stroke and Alzheimer’s diseases. One BC treatment called aromatase inhibitors appear to increase the risk of cardiovascular mortality by 50%. Despite this, very few studies have looked at the direct effects of aromatase inhibitors on the heart, vessels, and other early risk factorsfor cardiovascular disease. Thisstudy will be the first to examine the short- and long-term impact of aromatase inhibitors on a suite of health indicesrelated to heart, vessel, and brain health in BC survivors.
Competitiondate
202302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kirkham, Amy A
Approvedterm
1 an 0 mois
Cihrcontribution2
ICR~ $62,500~ $0~